A Phase 2 interventional study of Azenosertib in Uterine Serous Carcinoma, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. Completed at 56 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Histologically confirmed recurrent or persistent USC for which no other proven effective treatment options are available or any available standard of care therapy was not tolerated or was refused by the subject.
Required prior therapy for endometrial cancer:
EXCLUSION CRITERIA
Any of the following treatment interventions within the specified time frame prior to C1D1:
Azenosertib (ZN-c3) taken orally with food
Drug: Azenosertib
Azenosertib is an investigational drug.
Also known as: ZN-c3
Frequency and severity of TEAEs
To determine the safety and tolerability of ZN-c3 in subjects with recurrent or persistent USC.
Time frame: 2 years
Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICR
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC
Time frame: 2 years
Objective Response Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator.
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules
Time frame: 2 years
Duration of Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator.
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules
Time frame: 2 years
Progression Free Survival as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator.
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules
Time frame: 2 years
Clinical Benefit Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator.
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules
Time frame: 2 years
Time To Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator.
To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules
Time frame: 2 years
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc